[Immunomodulation by tacrolimus in atopic dermatitis].
Atopic dermatitis is a common allergic disease, in which the treatment is extremely complex; even when several immunological abnormalities have been described in atopic dermatitis, the immune response to drugs remains unclear for both: conventional and unconventional therapies. The present review is centered on clinical efficacy and safety of tacrolimus, one of the immunomodulators proposed to treat atopic dermatitis. There are clinical evidences to support that tacrolimus have considerable impact on expression of inflammatory markers, despite of clinical assays could be necessary to demonstrate its profiles of toxicity and efficacy, during long-time periods.
Rodríguez Orozco
Alain R
AR
Laboratorio de Inmunología, Universidad Michoacana de San Nicolás de Hidalgo. arorozco@hotmail.com
Ruiz Reyes
Héctor
H
D065095:Calcineurin Inhibitors; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000096:biosynthesis / Q000235:genetics; D004268:DNA-Binding Proteins / Q000037:antagonists & inhibitors; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D004311:Double-Blind Method; D004347:Drug Interactions; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D015337:Multicenter Studies as Topic; D050778:NFATC Transcription Factors; D009687:Nuclear Proteins / Q000037:antagonists & inhibitors; D010146:Pain / Q000139:chemically induced; D016559:Tacrolimus / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D022021:Tacrolimus Binding Proteins / Q000502:physiology; D014157:Transcription Factors / Q000037:antagonists & inhibitors; D016896:Treatment Outcome
D065095:Calcineurin Inhibitors; D016207:Cytokines; D004268:DNA-Binding Proteins; D007155:Immunologic Factors; D050778:NFATC Transcription Factors; D009687:Nuclear Proteins; D014157:Transcription Factors; D022021:Tacrolimus Binding Proteins; D016559:Tacrolimus